The strong bleeding reduction data de-risks the VM program and supports potential Breakthrough Therapy designation pursuit. Watch for FDA meeting outcomes and Phase 3 initiation timeline. The small sample (n=4 for bleeding endpoint) limits statistical power but the effect size is compelling for a rare disease.
Price Chart
Executive Summary
Palvella presented positive Phase 2 TOIVA data at SID showing QTORIN rapamycin statistically significantly reduced bleeding in cutaneous venous malformation patients (100% of bleeding patients improved, mean +2.5 on cVM-IGA Bleeding, p=0.003). The data supports the drug's potential as the first FDA-approved therapy for this rare disease with >75,000 U.S. patients, but remains early-stage with no regulatory submission yet.
Key Facts
- 100% of patients with bleeding at baseline (n=4) showed improvement on cVM-IGA Bleeding at Week 12, with mean +2.5 point improvement (p=0.003)
- 100% of bleeding patients reported being 'satisfied' or 'very satisfied' with QTORIN rapamycin on TSQM at Week 12
- Phase 2 TOIVA is a single-arm, open-label, baseline-controlled trial; no comparator arm
- QTORIN rapamycin has potential to be first FDA-approved therapy for cutaneous venous malformations (>75,000 U.S. patients)
- Data presented at 83rd SID Annual Meeting; previously announced statistical significance on multiple endpoints in December 2025
Financial Impact
Early-stage biotech with $1.7B market cap; positive Phase 2 data supports pipeline value but no revenue yet. Addressable U.S. population >75,000 patients for a potential first-in-class therapy.
Risk Factors
- Phase 2 single-arm design with small sample size (n=4 for bleeding endpoint) limits generalizability
- No FDA-approved comparator; regulatory path uncertain for novel endpoint (cVM-IGA Bleeding)
- Clinical-stage biotech with no approved products; requires additional capital for Phase 3 and potential commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access